Dyslipidaemia and renal disease - pathophysiology and lipid lowering therapy in patients with impaired renal function
Journal of Clinical and Basic Cardiology 2000; 3 (1): 3-6
Keywords: Dyslipidämie, Fibrate, Gallensäure, Lipidapherese, Lipidsenkung, Nierenerkrankung, Nikotinsäurederivate, Statin, bile acid binding resins, dyslipidaemia, fibrates, lipid apheresis, lipid lowering, nicotinic acid derivatives, renal disease, Statin
Dyslipidaemia is a consequence of renal disease, especially the nephrotic syndrome, wherein hepatic synthesis of lipoproteins is increased and clearance decreased. The resulting lipoprotein phenotype is highly atherogenic and significantly increases the cardiovascular risk of the patients. Additionally hyperlipidaemia accelerates the progression of human renal disease and therefore its therapeutic control seems to be an important component in the treatment regimen of patients with chronic renal failure. Intensive lipid lowering by LDL apheresis was accompanied by a reduction of proteinuria in diabetic patients with a nephrotic syndrome. Several studies could demonstrate that statins reveal - beside their lipid lowering properties - a renoprotective effect by reducing glomerular cell proliferation and macrophage infiltration. Accumulating data thus indicates that lipid lowering therapy in chronic renal failure is of importance not only with respect to the cardiovascular risk of the patients but also to retard the progression of renal disease. J Clin Basic Cardiol 2000; 3: 3-6.